Background: We compared the degree of systemic inflammation and its relationship to the angiographic outcomes after drug-eluting stent (DES) implantations.
Methods: We implanted a single DES in 79 stable angina patients (50 men; 60.4±9.5 years of age; sirolimus-eluting stent (SES), n=38; paclitaxel-eluting stent (PES), n=41). The hs-CRP and IL-6 levels were determined before and at 24, 72 hours, and 4 weeks after the PCI. An angiography and IVUS were performed.
Results: The hs-CRP and IL-6 levels at baseline did not differ between the two groups. The hs-CRP increased significantly from baseline at 24 hr and 72 hr after the PCI in both groups and there was a significant increase in the IL-6 level at 24 hr after the PCI in both groups. However, there was no significant difference between the two groups in any of the hs-CRP or IL-6 measurements. At follow up, the late lumen loss was significantly higher in the PES group than in the SES group (0.57±0.56 mm vs. 0.28±0.58 mm, respectively, p=0.020). The neointimal hyperplasia (NIH) volume in the PES group was significantly higher than that in the SES group (23.1±22.7 vs. 3.8±7.1 mm3, respectively, p=0.000). The percent luminal volume reduction was higher in the PES group than in the SES group (18.9 vs. 3.9 %, p=0.002). The absolute values or change in the inflammatory markers did not correlate with the NIH or stent volume reduction.
Conclusions: Our study showed that the benefits obtained from the SESs, which reduce neointimal proliferation, are not likely mediated by the attenuation of the systemic inflammatory markers, hs-CRP or IL-6.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.